Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 82

Explainer

Tirzepatide dosing: what the trials used

A trial-by-trial map of the dose escalation schedules used across the SURPASS and SURMOUNT programmes, with what each schedule produced at the primary endpoint.

8 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tirzepatide history: discovery to approval

Six milestones trace how tirzepatide went from a laboratory dual-agonist hypothesis in 2018 to one of the most-studied prescription medicines in the world.

8 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

SURMOUNT-OSA post-hoc: who benefits most

SURMOUNT-OSA post-hoc (Sleep, 2026): more-symptomatic patients saw larger subjective gains; objective AHI and weight changes were consistent across subgroups.

8 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Country deep-dive

What BPC-157 costs in Denmark

BPC-157 has no marketing authorisation in Denmark: no official price, no pharmacy route, no reimbursement. What the grey-market reality looks like.

7 Jul 2026 · PeptideMethods Editorial Team · 6 min read
Country deep-dive

BPC-157 Denmark: import rules explained

BPC-157 is unauthorised in Denmark. The 2026 personal import rules explicitly restrict doping substances. What the DKMA says and what customs flags.

7 Jul 2026 · PeptideMethods Editorial Team · 7 min read
Explainer

Tesamorelin: from discovery to FDA approval

How tesamorelin moved from a lab compound to FDA approval in 2010, and why the European application was withdrawn in 2012.

7 Jul 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

How Tesamorelin works: the mechanism

Tesamorelin binds GHRH receptors in the pituitary, triggers GH pulses, and raises IGF-1. Plain-English guide to the mechanism.

7 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

Tesamorelin side effects and safety data

The FDA label and phase-3 trials list injection site reactions, arthralgia, edema, and a threefold rise in new-onset dysglycemia. Here is what the data show.

7 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Country deep-dive

What tirzepatide costs in Germany

Cash prices, GKV reimbursement rules, PKV coverage, and the AMNOG process that determines what Mounjaro costs in Germany in 2026.

7 Jul 2026 · PeptideMethods Editorial Team · 7 min read
Country deep-dive

Tirzepatide Germany: import rules explained

Tirzepatide is EU-authorised as Mounjaro in Germany. What AMG § 73 says about importing it from outside the EU, grey-market risks, and how to get it legally.

7 Jul 2026 · PeptideMethods Editorial Team · 7 min read
Explainer

Semaglutide around knee replacement surgery

A pilot RCT sets out a 48-week semaglutide protocol around total knee replacement in obese patients. Here is what the paper covers and what remains unanswered.

6 Jul 2026 · PeptideMethods Editorial Team · 4 min read
Explainer

NITs in MASH: disease-activity vs response

A 2026 letter argues non-invasive liver tests after semaglutide reflect disease activity, not validated response. Here is what that means for MASH trial design.

6 Jul 2026 · PeptideMethods Editorial Team · 4 min read